FDA Warns DTC Genetic Test Firms
This article was originally published in The Tan Sheet
Executive Summary
The warning letters are the first FDA sent since it carved out a de novo risk category for DTC carrier screening tests, clearing the path for 23andMe Inc. to relaunch its Personal Genome Service in October.